Cyfuse Biomedical K.K. (4892) AI Stock Analysis

• Market Cap: ¥5.69B
• Dividend Yield: N/A
• Average Volume (3M): 197.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 8.12%
• EPS Growth: -19.12%
• Country: JP
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -28.96
• Shares Outstanding: 9,604,800
• 10 Day Avg. Volume: 445,220
• 30 Day Avg. Volume: 197,870
• PEG Ratio: -0.10
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 66.83
• P/FCF Ratio: -4.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥891.00
• Price Target Upside: 50.51% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ¥891.00 ▲(50.51% Upside)

The overall stock score reflects the significant financial and technical challenges facing the company. Persistent financial losses, negative cash flows, and bearish technical indicators are the primary factors influencing this score. The negative P/E ratio exacerbates valuation concerns, making it a high-risk investment.

Cyfuse Biomedical K.K. Business Overview & Revenue Model

Company Description

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.

How the Company Makes Money

Cyfuse Biomedical K.K. generates revenue primarily through the sale and licensing of its 3D bioprinting technology and related products. The company's proprietary Regenova bioprinter is sold to research institutions, pharmaceutical companies, and biotechnology firms seeking to advance their capabilities in tissue engineering and regenerative medicine. Additionally, Cyfuse may earn income through collaborative research and development partnerships, where they work with other entities to co-develop new applications and products utilizing their bioprinting technology. Revenue is also derived from providing technical and consultancy services related to the application of their bioprinting solutions.

Cyfuse Biomedical K.K. Financial Statement Overview

Summary

The company faces significant financial challenges, with declining revenue, persistent losses, and negative cash flows indicating operational difficulties. Despite a strong liquidity position, the declining equity and persistent losses highlight the need for strategic improvements.

Income Statement

The company's income statement presents concerning trends with consistent negative net income and deteriorating revenue growth. The Gross Profit Margin has decreased from 52.8% in 2021 to 29.6% in 2024, indicating declining profitability. The Net Profit Margin is negative, reflecting substantial losses. Revenue has decreased significantly from 2021 to 2024, highlighting a challenging market position and potential operational issues. While there was a positive EBIT margin in 2021, it has turned negative in subsequent years, indicating worsening operational profitability.

Balance Sheet

The balance sheet shows a moderately strong equity position with an Equity Ratio of approximately 72.3% in 2024. However, the Debt-to-Equity Ratio remains manageable at 0.34, indicating moderate leverage. There is a consistent decline in Stockholders' Equity from 2021 to 2024, which may impact future financial stability. Despite these concerns, the company maintains a significant cash position, suggesting liquidity is not an immediate issue.

Cash Flow

The cash flow statement reflects negative operating cash flow in recent years, raising concerns about cash generation from core operations. The Free Cash Flow has also been negative, indicating cash outflow challenges. The Operating Cash Flow to Net Income Ratio and Free Cash Flow to Net Income Ratio are negative, underscoring inefficiencies in converting revenue into cash flow. While the company has maintained some liquidity, the negative trends in cash flow present long-term sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.42M	54.45M	61.11M	374.48M	708.25M	137.48M
Gross Profit	14.66M	16.45M	37.74M	241.50M	570.60M	67.02M
EBITDA	-795.37M	-824.22M	-538.29M	-410.21M	168.65M	-288.66M
Net Income	-827.52M	-872.24M	-589.21M	-473.96M	142.91M	-329.50M
Balance Sheet
Total Assets	3.23B	3.52B	4.21B	4.82B	2.65B	2.20B
Cash, Cash Equivalents and Short-Term Investments	2.70B	3.05B	3.87B	4.44B	2.41B	2.07B
Total Debt	766.00M	852.00M	913.00M	908.14M	569.06M	529.54M
Total Liabilities	901.89M	975.60M	1.01B	1.05B	746.12M	646.75M
Stockholders Equity	2.33B	2.54B	3.20B	3.77B	1.90B	1.55B
Cash Flow
Free Cash Flow	0.00	-769.10M	-581.77M	-631.87M	161.54M	-294.26M
Operating Cash Flow	0.00	-760.55M	-562.30M	-403.60M	161.54M	-294.00M
Investing Cash Flow	0.00	-8.64M	-19.47M	-430.67M	-50.58M	-264.00K
Financing Cash Flow	0.00	-52.01M	18.24M	2.66B	229.21M	488.90M

Cyfuse Biomedical K.K. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 592.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 592 is below the 20-day moving average (MA) of 599.65, below the 50-day MA of 630.22, and below the 200-day MA of 764.90, indicating a neutral trend. The MACD of -8.44 indicates Negative momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 17.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.

Cyfuse Biomedical K.K. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	65 Neutral	¥8.92B	19.23	―	2.52%	-0.09%	-29.95%
4582	51 Neutral	¥6.80B	―	―	―	-50.88%	-22.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4892	44 Neutral	¥5.69B	―	―	―	8.12%	-19.12%
4586	41 Neutral	¥7.90B	―	―	―	-82.19%	-106.15%
4883	39 Underperform	¥6.41B	―	―	―	―	64.87%
4597	37 Underperform	€9.09B	―	-122.54%	―	84.28%	-17.32%